批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2012/08/31 |
SUPPL-27(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/07/06 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/04/23 |
SUPPL-22(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2002/11/19 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/06/26 |
SUPPL-19(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1995/08/28 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1995/06/26 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1995/01/24 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1994/11/29 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1994/11/01 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1994/11/01 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1994/05/31 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1994/03/02 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1993/12/21 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1993/12/20 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1993/09/17 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
;Orphan
|
|
|
1993/07/29 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:FELBAMATE 剂型/给药途径:TABLET;ORAL 规格:400MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020189 |
001 |
NDA |
FELBATOL |
FELBAMATE |
TABLET;ORAL |
400MG |
Prescription |
Yes |
No |
AB |
1993/07/29
|
MYLAN SPECIALITY LP |
201680 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
400MG |
Prescription |
No |
No |
AB |
2011/09/13
|
AMNEAL PHARMS |
202284 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
400MG |
Prescription |
No |
No |
AB |
2015/11/04
|
ANI PHARMS |
204595 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
400MG |
Prescription |
No |
No |
AB |
2016/01/11
|
ALVOGEN |
207093 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
400MG |
Prescription |
No |
No |
AB |
2017/04/20
|
TARO |
208970 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
400MG |
Prescription |
No |
No |
AB |
2017/05/30
|
ZYDUS LIFESCIENCES |
活性成分:FELBAMATE 剂型/给药途径:TABLET;ORAL 规格:600MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020189 |
002 |
NDA |
FELBATOL |
FELBAMATE |
TABLET;ORAL |
600MG |
Prescription |
Yes |
Yes |
AB |
1993/07/29
|
MYLAN SPECIALITY LP |
201680 |
002 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
600MG |
Prescription |
No |
No |
AB |
2011/09/13
|
AMNEAL PHARMS |
202284 |
002 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
600MG |
Prescription |
No |
No |
AB |
2015/11/04
|
ANI PHARMS |
204595 |
002 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
600MG |
Prescription |
No |
No |
AB |
2016/01/11
|
ALVOGEN |
207093 |
002 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
600MG |
Prescription |
No |
No |
AB |
2017/04/20
|
TARO |
208970 |
002 |
ANDA |
FELBAMATE |
FELBAMATE |
TABLET;ORAL |
600MG |
Prescription |
No |
No |
AB |
2017/05/30
|
ZYDUS LIFESCIENCES |
活性成分:FELBAMATE 剂型/给药途径:SUSPENSION;ORAL 规格:600MG/5ML 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020189 |
003 |
NDA |
FELBATOL |
FELBAMATE |
SUSPENSION;ORAL |
600MG/5ML |
Prescription |
Yes |
Yes |
AB |
1993/07/29
|
MYLAN SPECIALITY LP |
202385 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
SUSPENSION;ORAL |
600MG/5ML |
Prescription |
No |
No |
AB |
2011/12/16
|
AMNEAL PHARMS |
206314 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
SUSPENSION;ORAL |
600MG/5ML |
Prescription |
No |
No |
AB |
2017/06/16
|
TARO |
211333 |
001 |
ANDA |
FELBAMATE |
FELBAMATE |
SUSPENSION;ORAL |
600MG/5ML |
Prescription |
No |
No |
AB |
2019/05/31
|
NOVITIUM PHARMA |